IL317609A - Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof - Google Patents
Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereofInfo
- Publication number
- IL317609A IL317609A IL317609A IL31760924A IL317609A IL 317609 A IL317609 A IL 317609A IL 317609 A IL317609 A IL 317609A IL 31760924 A IL31760924 A IL 31760924A IL 317609 A IL317609 A IL 317609A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- acid sequence
- amino acid
- variant
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (35)
1. 93
2. CLAIMS It is claimed: 1. An isolated human interleukin 12 (IL-12) variant comprising an amino acid substitution at position Y167 of SEQ ID NO: 1 (IL-12 p35 subunit) and position D93 of SEQ ID NO: 2 (IL-12 p40 subunit). 2. The IL-12 variant of claim 1, wherein the Y167 substitution is Y167A
3. The IL-12 variant of any one of claims 1-2, wherein the D93 substitution is D93L
4. The IL-12 variant of any one of claims 1-3, wherein the Y167 substitution is Y167A and the D93 substitution is D93L.
5. The IL-12 variant of any one of claims 1-4, wherein the p40 subunit further comprises one or more mutations to reduce the binding of IL-12 to heparin.
6. The IL-12 variant of claim 5, wherein the mutations to reduce the binding of IL-to heparin comprise the substitutions K258G, S259G, and K260G, and deletions of R261, E262, K263, and K264 of SEQ ID NO: 2.
7. An isolated human interleukin 12 (IL-12) variant comprising one or both of i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 3 (variant IL-12 psubunit) and ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: (variant IL-12 p40 subunit).
8. An isolated human interleukin 12 (IL-12) variant comprising an amino acid substitution at one or more of positions: F39 of SEQ ID NO: 1 (IL-12 p35 subunit), Iof SEQ ID NO: 1, Y167 of SEQ ID NO: 1, K85 of SEQ ID NO: 2 (IL-12 p40 subunit) and D93 of SEQ ID NO: 2.
9. The IL-12 variant of claim 8, wherein the F39 substitution is F39R or F39A, the Isubstitution is I52E, I52R, or I52H, the Y167 substitution is Y167A, the Ksubstitution is K85E, and the D93 substitution is D93L.
10. The IL-12 variant of any one of claims 8-9, wherein the p40 subunit further comprises one or more mutations to reduce the binding of IL-12 to heparin. 94
11. The IL-12 variant of any one of claims 1-10, wherein the IL-12 variant has reduced activity as compared to wild-type human IL-12.
12. An isolated antibody that binds to PD1 and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NOs: 9, 35, or 36, the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 10 or 37, the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 11, the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 12, the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 14.
13. The antibody of claim 12, wherein the VH comprises the amino acid sequence of SEQ ID NO: 7 and the VL comprises the amino acid sequence of SEQ ID NO: 8.
14. An isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 5, 51 or 52 and a light chain comprising the amino acid sequence of SEQ ID NO: 6, wherein the C-terminal lysine of SEQ ID NO: 5, 51, or is optional.
15. An isolated antibody that binds to PD1 and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 19, 35, or 36, the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 20 or 37, the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 21, the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 22, the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 23, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 24.
16. An isolated antibody that binds to PD1 and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 9, 35, or 36, the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 38 or 39, the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 21, the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 12, the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 40, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 41. 95
17. The antibody of any one of claims 12-16, wherein the antibody does not block the binding of PDL1 to PD1.
18. An isolated fusion protein comprising a human interleukin 12 (IL-12) variant of any one of claims 1-11 linked to an anti-PD1 antibody.
19. The fusion protein of claim 18, wherein the anti-PD1 antibody is the antibody of any one of claims 12-16.
20. The fusion protein of any one of claims 18-19, wherein the IL-12 variant comprises an amino acid substitution at position Y167 of SEQ ID NO: 1 (IL-12 psubunit) and position D93 of SEQ ID NO: 2 (IL-12 p40 subunit).
21. The fusion protein of any one of claims 18-20, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence of SEQ ID NO: 7 and the VL comprises the amino acid sequence of SEQ ID NO: 8.
22. An isolated fusion protein comprising a human interleukin 12 (IL-12) variant and an anti-PD1 antibody, wherein the fusion protein comprises the polypeptides of SEQ ID NOs: 5, 25, 6, and 4.
23. An isolated fusion protein comprising a human interleukin 12 (IL-12) variant and an anti-PD1 antibody, wherein the fusion protein comprises the polypeptides of SEQ ID NOs: 15, 26, 16, and 4.
24. An isolated polynucleotide or polynucleotides comprising one or more nucleotide sequences encoding one or more of the IL-12 variants, anti-PD1 antibodies, fusion proteins or a polypeptide thereof of any one of claims 1-23.
25. An isolated polynucleotide or polynucleotides comprising one or more nucleotide sequences of encoding a human interleukin 12 (IL-12) variant comprising an amino acid substitution at position Y167 of SEQ ID NO: 1 (IL-12 p35 subunit) and position D93 of SEQ ID NO: 2 (IL-12 p40 subunit), wherein the one or more nucleotide sequences comprise a nucleotide sequence of SEQ ID NO: 44 and a nucleotide sequence of SEQ ID NO: 45. 96
26. An isolated polynucleotide or polynucleotides comprising one or more nucleotide sequences encoding the VH, VL, or both of an antibody that binds PD1, wherein the polynucleotide(s) comprise the VH nucleic acid sequence of SEQ ID NO: 46, the VL nucleic acid sequence of SEQ ID NO: 47, or both the VH nucleic acid sequence of SEQ ID NO: 46 and the VL nucleic acid sequence of SEQ ID NO: 47.
27. An isolated polynucleotide or polynucleotides comprising one or more nucleotide sequences encoding any one or more of the heavy chain, light chain, IL-12 psubunit, or heavy chain-IL12 p35 fusion polypeptide of a fusion protein comprising a human IL-12 variant and an anti-PD1 antibody, wherein the polynucleotide(s) comprise the heavy chain nucleic acid sequence of SEQ ID NO: 48, the light chain nucleic acid sequence of SEQ ID NO: 50, the IL-12 p40 subunit nucleic acid sequence of SEQ ID NO: 45, the heavy chain-IL12 p35 fusion polypeptide nucleic acid sequence of SEQ ID NO: 49 or each of the heavy chain nucleic acid sequence of SEQ ID NO: 48, the light chain nucleic acid sequence of SEQ ID NO: 50, the IL-p40 subunit nucleic acid sequence of SEQ ID NO: 45, and the heavy chain-IL12 pfusion polypeptide nucleic acid sequence of SEQ ID NO: 49.
28. An isolated polynucleotide or polynucleotides comprising one or more nucleotide sequences encoding any one or more of the heavy chain, light chain, IL-12 psubunit, or heavy chain-IL12 p35 fusion polypeptide of a fusion protein comprising a human IL-12 variant and an anti-PD1 antibody, wherein the polynucleotide(s) comprise the heavy chain encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127517, the light chain encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127519, the IL-p40 subunit encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127520, the heavy chain-IL12 p35 fusion polypeptide encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-1275, or each of the heavy chain encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127517, the light chain encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127519, the IL-p40 subunit encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127520, and the heavy chain-IL12 p35 fusion polypeptide encoding nucleic acid sequence of the insert of the 97 plasmid deposited with the ATCC and having ATCC Accession Number PTA-127518.
29. A vector comprising the polynucleotide or polynucleotides of any one of claims 24-28.
30. An isolated host cell comprising the polynucleotide or polynucleotides of any one of claims 24-28 or the vector of claim 29.
31. A method of producing an IL-12 variant, anti-PD1 antibody, or fusion protein comprising culturing the host cell of claim 30 under conditions that result production of the IL-12 variant, anti-PD1 antibody, or fusion protein, and optionally further recovering the IL-12 variant, anti-PD1 antibody, or fusion protein.
32. A pharmaceutical composition comprising the IL-12 variant, anti-PD1 antibody, or fusion protein of any one of claims 1-23 and a pharmaceutically acceptable carrier.
33. The IL-12 variant, anti-PD1 antibody, or fusion protein of any one of claims 1-or the pharmaceutical composition of claim 32 for use as a medicament, optionally for use as a medicament for the treatment of cancer.
34. The IL-12 variant, anti-PD1 antibody, fusion protein, or pharmaceutical composition for use of claim 33 wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma [squamous cell carcinoma of the head and neck (SCCHN)], lung squamous cell carcinoma, lung adenocarcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma (RCC), small-cell lung cancer (SCLC), triple negative breast cancer, urothelial cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin’s lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin’s lymphoma (NHL), small lymphocytic lymphoma (SLL), endometrial cancer, B-cell acute lymphoblastic leukemia, colorectal cancer (CRC), glioblastoma, uterine cancer, cervical cancer, penile cancer, gastric cancer (GC) or non-melanoma skin cancer. 98
35. The IL-12 variant, anti-PD1 antibody, fusion protein, or pharmaceutical composition for use of claim 33 or 34, wherein the cancer was previously treated with a PD(L)1 inhibitor which is different than the anti-PD1 antibody of any one of claims 12-17.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263353241P | 2022-06-17 | 2022-06-17 | |
| US202363496545P | 2023-04-17 | 2023-04-17 | |
| PCT/IB2023/056152 WO2023242769A1 (en) | 2022-06-17 | 2023-06-14 | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317609A true IL317609A (en) | 2025-02-01 |
Family
ID=86899441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317609A IL317609A (en) | 2022-06-17 | 2023-06-14 | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240010696A1 (en) |
| EP (1) | EP4540278A1 (en) |
| JP (1) | JP2025520411A (en) |
| KR (1) | KR20250010064A (en) |
| CN (1) | CN120035602A (en) |
| AU (1) | AU2023294103A1 (en) |
| CA (1) | CA3259654A1 (en) |
| CO (1) | CO2024017318A2 (en) |
| IL (1) | IL317609A (en) |
| MX (1) | MX2024015610A (en) |
| PE (1) | PE20250875A1 (en) |
| TW (1) | TW202409067A (en) |
| WO (1) | WO2023242769A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200089312A (en) | 2017-11-28 | 2020-07-24 | 추가이 세이야쿠 가부시키가이샤 | Ligand binding molecule capable of modulating ligand binding activity |
| EP3981428A4 (en) | 2019-06-05 | 2023-07-12 | Chugai Seiyaku Kabushiki Kaisha | PROTEAS SUBSTRATE AND POLYPEPTIDE WITH PROTEAS CLEAVAGE SEQUENCE |
| CN115943210A (en) | 2020-01-20 | 2023-04-07 | 中外制药株式会社 | ligand-binding fusion protein |
| WO2024148369A1 (en) * | 2023-01-07 | 2024-07-11 | Lyell Immunopharma, Inc. | Targeted il-12 affinity variants |
| CN120230225A (en) * | 2024-02-07 | 2025-07-01 | 上海交通大学 | Activity-regulatable IL-12 fusion protein and its use |
| WO2025252212A1 (en) * | 2024-06-07 | 2025-12-11 | 福佑泰生物制药公司 | Immunoconjugate of anti-pd-1 antibody and cytokine il-12 mutant protein, and use thereof |
| CN120077060A (en) * | 2024-08-16 | 2025-05-30 | 程联胜 | Interleukin 12 mutants and uses thereof |
| US20260083857A1 (en) * | 2024-09-23 | 2026-03-26 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugate formulations |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2002522063A (en) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | Generation of modified molecules with increased serum half-life |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| SI1966238T1 (en) * | 2005-12-30 | 2012-08-31 | Merck Patent Gmbh | Interleukin-12p40 variants with improved stability |
| CA2676529C (en) | 2007-01-24 | 2014-03-25 | Kyowa Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
| SI2242771T1 (en) | 2007-12-14 | 2013-09-30 | Bristol-Myers Squibb Company | Binding molecules to the human ox40 receptor |
| WO2011112935A2 (en) * | 2010-03-12 | 2011-09-15 | The Regents Of The University Of California | Antibody fusion proteins with disrupted heparin-binding activity |
| SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| MX2016017393A (en) | 2014-07-01 | 2017-09-05 | Pfizer | Bispecific heterodimeric diabodies and uses thereof. |
| TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-PD-1 antibodies and methods of using same |
| HUE057285T2 (en) | 2015-04-13 | 2022-04-28 | Pfizer | Therapeutic antibodies and their uses |
| CN111148762A (en) | 2017-05-31 | 2020-05-12 | 斯特库伯株式会社 | Antibodies and molecules that immunospecifically bind to BTN1a1 and therapeutic uses thereof |
| JP7234142B2 (en) | 2017-06-02 | 2023-03-07 | ファイザー・インク | Antibodies specific for FLT3 and uses thereof |
| KR102884523B1 (en) * | 2018-10-03 | 2025-11-10 | 젠코어 인코포레이티드 | IL-12 heterodimeric Fc-fusion protein |
| EP4037700A2 (en) * | 2019-10-03 | 2022-08-10 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
| MX2022011676A (en) * | 2020-03-23 | 2023-03-08 | Zymeworks Bc Inc | Masked il12 fusion proteins and methods of use thereof. |
| WO2022094046A1 (en) * | 2020-10-29 | 2022-05-05 | Proviva Therapeutics (Hong Kong) Limited | Il-12 compositions and methods of use thereof |
| AU2022314734A1 (en) * | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| CA3232632A1 (en) * | 2021-09-17 | 2023-03-23 | Bicara Therapeutics Inc. | Caix targeting il-12 fusion proteins and methods of use thereof |
-
2023
- 2023-06-14 CN CN202380058256.5A patent/CN120035602A/en active Pending
- 2023-06-14 KR KR1020247041244A patent/KR20250010064A/en not_active Withdrawn
- 2023-06-14 IL IL317609A patent/IL317609A/en unknown
- 2023-06-14 EP EP23733074.1A patent/EP4540278A1/en active Pending
- 2023-06-14 JP JP2024573417A patent/JP2025520411A/en active Pending
- 2023-06-14 WO PCT/IB2023/056152 patent/WO2023242769A1/en not_active Ceased
- 2023-06-14 AU AU2023294103A patent/AU2023294103A1/en active Pending
- 2023-06-14 CA CA3259654A patent/CA3259654A1/en active Pending
- 2023-06-14 PE PE2024002938A patent/PE20250875A1/en unknown
- 2023-06-15 US US18/335,259 patent/US20240010696A1/en active Pending
- 2023-06-16 TW TW112122623A patent/TW202409067A/en unknown
-
2024
- 2024-12-13 MX MX2024015610A patent/MX2024015610A/en unknown
- 2024-12-17 CO CONC2024/0017318A patent/CO2024017318A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3259654A1 (en) | 2023-12-21 |
| CO2024017318A2 (en) | 2024-12-30 |
| AU2023294103A1 (en) | 2024-12-19 |
| PE20250875A1 (en) | 2025-03-28 |
| JP2025520411A (en) | 2025-07-03 |
| KR20250010064A (en) | 2025-01-20 |
| MX2024015610A (en) | 2025-02-10 |
| WO2023242769A1 (en) | 2023-12-21 |
| EP4540278A1 (en) | 2025-04-23 |
| US20240010696A1 (en) | 2024-01-11 |
| TW202409067A (en) | 2024-03-01 |
| CN120035602A (en) | 2025-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3031002T3 (en) | T cell recruiting polypeptides based on tcr alpha/beta reactivity | |
| CN104403004B (en) | Preparation and use of antibody-interferon heterodimer | |
| AU2002357784B2 (en) | Immunocytokines with modulated selectivity | |
| US20200087377A1 (en) | Multifunctional Fusion Protein and Applications Thereof | |
| JP2024075737A5 (en) | ||
| EP4509186A2 (en) | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof | |
| JP5324593B2 (en) | Inhibition of macrophage stimulating protein receptor (RON) and methods of treatment thereof | |
| JP2022509065A5 (en) | ||
| JP2020511932A5 (en) | ||
| JP2022512043A5 (en) | ||
| AU2020289080A1 (en) | Multispecific proteins | |
| CN114514244B (en) | T cell activating antibodies | |
| EP3759229A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer | |
| RU2018147423A (en) | Anti-PD-L1 and IL-2 cytokines | |
| CN113637692A (en) | Immunomodulator | |
| JP2019531764A5 (en) | ||
| RU2012139197A (en) | MODIFIED ANTIGEN-BINDING MOLECULES WITH ALTERED CELL SIGNAL ACTIVITY | |
| US20220298212A1 (en) | Recombinant 4-1bb binding proteins and their use | |
| JP2021528047A5 (en) | ||
| JP2021521110A5 (en) | ||
| JP2023523083A5 (en) | ||
| JP2016504420A5 (en) | ||
| CN117679505A (en) | Drug combinations and uses | |
| JP2020536492A5 (en) | ||
| WO2018055503A1 (en) | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |